Whitley R J, Weiss H L, Soong S J, Gnann J W
Department of Pediatrics, University of Alabama at Birmingham, USA.
J Infect Dis. 1999 Jan;179(1):9-15. doi: 10.1086/314562.
Acute neuritis and persistent pain are the most significant clinical manifestations of herpes zoster and are end points for clinical trials therapy. In an acyclovir and prednisone study, patients were categorized according to pain severity and number of lesions at presentation. Risk categories were defined according to the magnitude of risk ratios (RRs) and a comparison of Kaplan-Meier survival estimates. For acute neuritis and zoster-associated pain, RRs defined rate of resolution. Patients who presented with severe or incapacitating pain and a large number of lesions were less likely to achieve resolution of both acute neuritis and zoster-associated pain (RR, 18.0; 95% confidence interval [CI], 6. 6-48.6, and RR, 5.3; 95% CI, 4.2-17.2, respectively). These analyses identify the subgroups of patients for whom aggressive interventions are most strongly indicated.
急性神经炎和持续性疼痛是带状疱疹最显著的临床表现，也是临床试验治疗的终点。在一项关于阿昔洛韦和泼尼松的研究中，患者根据就诊时的疼痛严重程度和皮损数量进行分类。风险类别根据风险比（RR）的大小以及Kaplan-Meier生存估计值的比较来定义。对于急性神经炎和带状疱疹相关性疼痛，RR定义了缓解率。出现严重或使人丧失能力的疼痛且有大量皮损的患者，急性神经炎和带状疱疹相关性疼痛同时缓解的可能性较小（RR分别为18.0；95%置信区间[CI]为6.6 - 48.6，以及RR为5.3；95%CI为4.2 - 17.2）。这些分析确定了最强烈提示需要积极干预的患者亚组。
